Value of three cardiac markers in the early diagnosis of acute myocardial infarction

Abstract

Abstract:

AIM: To explore the value of three cardiac markers in the early diagnosis of acute myocardial infarction(AMI). METHODS: 90 cases of AMI were selected as the experimental group, and were further divided into the (0-3 h) group (34 cases) and (3-6 h) group (56 cases) according to the on-set time. 80 cases of healthy check-ups were recruited in the control group, and another 20 cases of muscle injury were also selected in this experiment. High-sensitivity cardiac troponin I(hs-cTnI) ，heart fatty acid-binding protein (H-FABP) and myoglobin(MYO) were measured simultaneously. RESULTS:Serum concentrations of H-FABP, hs-cTnI and MYO in the 34 AMI patients of (0-3 h) group and 56 AMI patients level of the experimental group were higher than those of control group(P＜0.01); serum concentrations of MYO in patients with muscle injury were higher than those of control group(P＜0.01); the specificity and sensitivity of H-FABP and cTnI were higher than those of MYO within the early onset time of AMI (0-3 h, 3-6 h); hs-cTnI was more sensitive than cTnI in the early onset of AMI. CONCLUSION: H-FABP and hs-cTnI can be referential serum markers for early diagnosis of AMI.

Key words: acute myocardial infarction, high-sensitivity cardiac troponin I, heart fatty acid-binding protein, myoglobin, diagnostic value

CLC Number:

R972

PU Chun, TAO Qingsong, ZHU Xiang, QIN Mingming, WU Qiwen, FENG Gang. Value of three cardiac markers in the early diagnosis of acute myocardial infarction[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 82-86.

References

［1］Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acute myocardial infarction［J］. Am J Emerg Med, 2006, 24（2）:149-155.
［2］中华医学会心血管病学分会·中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南［J］. 中华心血管病杂志,2010,38(8):675-687.
［3］Liebetrau C, Nef HM, Do rr O, et al. Release kinetics of early ischaemic biomarkers is in a clinical model of a cute myocardial infarction［J］. Heart, 2014, 100(8):652-657.
［4］Flook N, Unge P, Agréus L, et al. Clinical Review: Approach to managing undiagnosed chest pain- Could gastro-oesophageal reflux disease be the cause ［J］? Can Fam Physician, 2007,53（2）:261-266.
［5］Alhashemi JA. Diagnostic accuracy of a bedside qualitative immunochromatographic test for acute myocardial infarction［J］. Am J Emerg Med, 2006, 24（2）:149-155.
［6］Adams J, Trent R, Rawles J. Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment［J］. BMJ,1993,307（6901）:409-413.
［7］Figiel L，Kasprzak JD，Peruqa J，et al. Heart-type fatty acid binding protein-a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation［J］. Kardiol Pol，2008，66(3): 253-259，260-261．
［8］Alhadi HA, Fox KAA. Do we need additional markers of myocyte necrosis: the potential value of heart type fatty acid binding protein［J］. Q J Med, 2004, 97:187-198.
［9］Vork MM, Glatz JF, Surtel DA, et al. A sandwich ELISA for the determination of rat H-FABP using Streptavidin-Biotin system［J］. Biochem Biophys Acta, 1991, 1075(3):199-205.
［10］Glatz JF, van der Vusse GJ, Simoons ML, et al. Fatty acid binding protein and early detection of acute myocardial infarction［J］. Clin Chem Acta, 1998,272(1):87-92.
［11］Banu S, Tanveer S, Manjunath CN. Comparative study of high sensitivity troponin T and heart-type fatty acid-binding protein in STEMI patients［J］. Saudi J Biol Sci, 2015, 22(1):56-61.
［12］Ramaiah JH, Ramegowda RT, Ashalatha B, et al. Heart-type fatty acid-binding protein (H-FABP) as a novel biomarker for the early diagnosis of acute myocardial infarction in comparison with cardiac troponin T［J］. J Evolution Med Dental Sci,2013，2(1):8-18.
［13］Chan CP, Sum KW, Cheung KY, et al. Development of a quantitative lateral-flow assay for rapid detection of fatty acid-binding protein［J］. J Immunol Methods, 2003, 279(1/2):91-100.
［14］Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays［J］. N Engl J Med, 2009, 361（9）:858-867.
［15］Diercks DB, Peacock WF 4th, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assayfor acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain［J］. Am Heart J, 2012, 163（1）:74-80.
［16］Meune C, Reichlin T, Irfan A, et al. How safe is the outpatient management of patients with acute chest pain and mildly increased cardiactroponin concentrations［J］? Clin Chem, 2012, 58(5):916-924.
［17］Chan D，Ng LL．Biomarkers in acute myocardial infarction［J］. BMC Med，2010, 8: 34．

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[3]	ZHAO Wei, WU Youyang, LIN Cong, HUANG Shiwei, CHEN Hao, JIANG Wenbing. Effects of pterostilbene on myocardial function, myocardial fibrosis and inflammatory response in rats with acute myocardial infarction and on Notch1/eIF3a signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 498-504.
[4]	CAI Hairui，CHENG Shuqing，LIU Xijuan,CHEN Aner. Diagnostic value of thyroid function in pregnant women with pre-eclampsia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 71-76.
[5]	LI Yi-min, HUANG Jin, LU Zhi-ping, LI Xiang-yu, HE Sheng-hu. Effects of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1403-1406.
[6]	LI Shu, ZHANG Gen-bao, HONG Yun, LU Xiao-hua. Study on mechanisms of Agkistrodon halyx pallas venom PCA to improve heart function in rats with acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 141-146.
[7]	QIAO Hua, HE Sheng-hu, JI Jun, CHEN Shu, LIU Xiao-dong, XU Ri-xing, XIE Yong. Effects of recombinant human brain natriuretic peptide in Non-ST-segment elevation acute myocardial infarction patients with heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1406-1409.
[8]	FANG Wu-wang, LIN bin-lai, ZHANG Sheng-xia, LIU Ling-ling, CHEN Shao-liang. Autologous bone marrow mesenchymal stem cell transplantation for acute myocardial infarction in pigs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 767-772.
[9]	XU Tong-tong, YANG Yue-zhong. Leptin level change during acute myocardial infarction in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 191-194.
[10]	SUN Chun-ling, HONG Hua-shan. Effect of cytokines on repairing myocardium in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(11): 1213-1218.
[11]	ZHANG Hang, CHEN Shao-Liang, SHAN Shou-Jie, YE Fei, DUAN Bao-Xiang, ZHANG Jun-Jie. Plaque morphological characteristics of acute myocardial infarction observed by intravascular ultrasound [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(6): 698-700.
[12]	LIU Li-Ping. Clinical efficacy of urokinase in treatment of senium acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 461-462.
[13]	CHEN Qian. Treatments of acute myocardial infarction with cardiogenic shock [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 465-466.
[14]	CHEN Min. Intra-aortic balloon pump counterpulsation (IABp)in treatment of thirty-three cases with high-dangerous acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 78-78.
[15]	CHEN Shao-Liang, YUAN Zen-Bai, YE Fei, FANG Wu-Wang, SONG Jie, TAN Huai-Qing, Tamari. Intracoronary adenosine decreases the incidence of no reflow during percutaneous intervention in patients with acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 295-300.